Objective: Because chylothorax complicating thoracic surgery is difficult to diagnose and failure of nonoperative management necessitates further surgery, we critically evaluated an evolving percutaneous strategy for diagnosing and treating chylothorax. Methods: After thoracic surgery, 37 patients with a clinical diagnosis of chylothorax were referred for lymphangiography for definitive diagnosis and percutaneous treatment. Successful localization of the cisterna chyli by lymphangiogram facilitated percutaneous cannulation of the thoracic duct and its embolization. In patients in whom cannulation was not possible, the thoracic duct was percutaneously disrupted. Results: Diagnosis: Lymphangiography was successful in 36 of the 37 patients (97%). Contrast extravasation, confirming clinical diagnosis, was present in 21 of the 36 (58%). Management: Twenty-one of 36 patients underwent 22 lymphangiographically directed percutaneous interventions: 12 embolizations and 10 disruptions. Mortality was zero, with two manageable complications. Patients without percutaneous intervention were discharged a median of 7 days (range 4-58) after first lymphangiography, 8 days (range 2-19) after percutaneous embolization, and 19 days (range 6-48) after first disruption. Eight patients had nine subsequent reoperations for chylothorax, two with negative lymphangiograms; no embolization patient required reoperation. Conclusions: There is a discrepancy between the clinical diagnosis of chylothorax after thoracic surgery and the presumed gold standard of diagnosis, contrast extravasation at lymphangiogram. Percutaneous treatment by thoracic duct embolization or disruption is safe and may obviate reoperation, but embolization of the thoracic duct is preferable to its disruption. #
Introduction
Large-volume chest tube drainage complicating thoracic surgery, suspicious for chylothorax, typically responds to nonoperative management. However, biochemical analysis of chest tube output may not be diagnostic of chylothorax because of the transitory postoperative state. Nonoperative management may not be successful, necessitating reoperation. Technological advances now permit percutaneous treatment of chylothorax, which has resurrected diagnostic lymphangiography in our institution. This study critically evaluates this evolving percutaneous strategy for diagnosing and treating chylothorax.
Patients and methods

Patients
Following 15,156 thoracic operations performed from 12/ 2003 to 12/2006, 37 patients had substantially increased or changing quality of chest tube drainage with gastrointestinal challenge and were referred for lymphangiography with a clinical diagnosis of chylothorax (Fig. 1) . Esophagectomy had been performed in 26 (70%), thoracic aortic aneurysm repair in four (11%), lung resection in three (8%), and coronary artery bypass grafting, mitral valve repair, heart transplant, and lung transplant in one (3%) each.
In one patient, lymphangiography was not possible because pedal lymphatics could not be cannulated. Among the 36 patients successfully cannulated, three repeat lymphangiograms were required. One patient had diagnostic lymphangiography demonstrating contrast extravasation, but percutaneous treatment was not attempted because of agitation; 7 days later, he had a repeat lymphangiography and embolization of the thoracic duct under general anesthesia. The second patient had lymphangiography and percutaneous disruption of the retroperitoneal lymphatics at the cisterna chyli-thoracic duct junction (hereafter called thoracic duct disruption); 15 days later he had thoracotomy with thoracic duct ligation and decortication, and 3 days later he underwent repeat lymphangiogram and repeat disruption of the thoracic duct. Eventually, a pleuro-peritoneal shunt was required for resolution of this recalcitrant chylothorax. The third patient underwent an unsuccessful attempt to cannulate the thoracic duct; 3 days later he had repeat lymphangiography and thoracic duct disruption.
Lymphangiography
Isosulfan blue dye (1% Lymphazurin, US Surgical, Norwalk CT) was injected intradermally into the dorsal aspect of the web spaces between toes of both feet ( Fig. 2A) . After approximately 30 min, lymphatic channels on the dorsal surfaces of the feet were identified by green subcutaneous paths. The foot with larger caliber lymphatic channels was sterilely prepared, and a pedal lymphatic was isolated by superficial dissection and cannulated with a 30-gauge catheter (Cook, Inc., Bloomington, IN) ( Fig. 2 middle, right) . Ethiodized oil (Ethiodol, Savage Laboratories, Melville, NY) was infused into the lymphatic by a flow-limited pump (0.5 ml min À1 ; total volume 12 ml). Spot fluoroscopy was obtained periodically to confirm adequate antegrade progression of contrast. Following completion of ethiodized oil injection, normal saline was infused at the same rate. The cisterna chyli and thoracic duct were usually opacified within 1-2 h (Fig. 3 left) . Large thoracic duct leaks were identified by frank extravasation of ethiodized oil into the mediastinum or pleural space (Fig. 3 middle) . In patients without contrast extravasation, computed thoracic tomography (CT) enhanced identification of extravasation [1] (Fig. 3 right) .
Percutaneous treatment
Once adequately opacified, the cisterna chyli was accessed percutaneously via a right posterior transhepatic approach with the patient in left posterior oblique position (Fig. 4) [2, 3] . A 20 cm 22-gauge Chiba needle (Cook, Inc, Bloomington, IN) was guided fluoroscopically into the cisterna chyli, and a coaxially steerable 80 cm 0.46 mm Nitrex guide wire (Microvena, White Bear Lake, MN) was advanced into the thoracic duct (Fig. 5 ). The inner two pieces (4-Fr dilator and locking cannula) of an Accustick II access cannula (Boston Scientific, Natick, MA) were advanced over the guide wire, positioning the plastic 4-Fr catheter within the thoracic duct. Water-soluble, non-ionic contrast material was injected to further evaluate the site of contrast extravasation or to increase the possibility of identifying extravasation if it was not seen on initial lymphangiogram. When extravasation was confirmed, the plastic cannula was exchanged over the guide wire for a microcatheter (Renegade, Boston Scientific, Natick, MA, or Rapid Transit, Cordis, Miami Lakes, FL), which was advanced to a position proximal to the extravasation. N-butyl cyanoacrylate (Trufill n-BCA, Cordis, Miami Lakes, FL) was diluted 1:3 with ethiodized oil and injected under fluoroscopic guidance until the thoracic duct proximal to the extravasation was opacified (Fig. 6 ). The microcatheter was removed promptly to avoid gluing it in place. Metallic embolization coils (Boston Scientific, Natick, MA) were used alone or adjunctively (Fig. 7) . The practice has evolved into embolization with coils followed by glue whenever possible. Occlusion of thoracic duct and leak cessation were confirmed by injecting a small amount of water-soluble non-ionic contrast. The plastic cannula was removed and the procedure concluded.
Prophylactic intravenous antibiotic (Ancef) was administered during the procedure.
When the cisterna chyli could be opacified but not percutaneously cannulated, its junction with the thoracic duct or neighboring retroperitoneal lymphatic ducts were disrupted as described by Cope and Kaiser [4] using a 21-or 22-gauge beveled needle maneuvered to and fro.
Results
Diagnosis
Prior to first attempted lymphangiogram for a clinical diagnosis of chylothorax, pleural fluid analysis was positive for triglycerides (>110 mg dl À1 ) in 14, negative in 11, and not done in 12. Chylomicrons were present in 16, negative in 11, and not done in 10. Either analysis was positive in 17, and neither done in eight. Thus, biochemical analyses were diagnostic in 59% of patients with the clinical diagnosis of chylothorax.
Of the 36 patients in whom lymphangiography was able to be performed (97%), contrast extravasation was observed in 20 (56%), equivocal in one (2.8%), and not observed in 15 (42%). Of the 16 with no or equivocal contrast extravasation, 12 CT scans were performed. Of these, no extravasation was observed in 11, but extravasation was confirmed in the patient with an equivocal lymphangiogram. Therefore, contrast extravasation was observed in 21 patients (58%; Fig. 1 ).
Of the 21 lymphangiograms with contrast extravasation, triglycerides were positive in nine, negative in seven, and not done in five; chylomicrons were positive in 10, negative in seven, and not done in four. Either analysis was positive in 11 and neither done in three, a positive biochemical diagnosis in 61% of patients with contrast extravasation. In the 15 patients without contrast extravasation, triglycerides were positive in five, negative in three, and not done in seven; chylomicrons were positive in six, negative in three, and not done in six. Either analysis was positive in six and neither done in five, a positive biochemical diagnosis in 60% of patients without contrast extravasation.
Percutaneous treatment
Percutaneous treatment was performed in 21 of the 36 patients (58%; Fig. 1 ). One patient required two interventions. Thoracic duct embolization was achieved in 12 patients (gluing only in four, coils only in three, and both in five), and 10 thoracic duct disruptions were performed in nine (two in one patient) (Fig. 1) . Disruption was performed when embolization was not possible because of inability to assess the cisterna chyli (n = 2), pass the guide wire cranially (n = 7), and advance the delivery device (n = 1).
Percutaneous treatment was performed in four patients with negative lymphangiograms: embolization in one and disruption in three (Fig. 1) . In two of these, it was believed that lymphangiography could be falsely negative because of prior lymphoma therapy or upper-extremity deep venous thrombosis. In two other patients with high pleural fluid output, respiratory failure or positive biochemical diagnosis led us to believe that lymphangiography could be falsely negative.
Four patients with contrast extravasation did not have percutaneous treatment (Fig. 1) . In two the cisterna chyli could not be accessed, and in one each unfavorable body habitus and thymic extravasation prevented percutaneous treatment.
Safety of percutaneous treatment
There was no mortality. After lymphangiogram, one patient aspirated and required intubation, but recovered fully. After percutaneous treatment, one patient suffered a bile leak that was diagnosed and managed by endoscopic cholangiography and bile duct stenting.
Efficacy of percutaneous treatment
Surgical reoperation for chylothorax was performed in eight patients (Fig. 1) . Right thoracotomy with thoracic duct ligation and decortication was performed in five (one of whom subsequently required a pleuro-peritoneal shunt), right thoracotomy and decortication in one, bilateral pleurex catheters in one, and oversewing of the thymus in one. Four of these reoperations occurred after disruption and four after no percutaneous treatment (two after lymphangiogram with contrast extravasation and two after lymphangiogram without contrast extravasation). No patient whose thoracic duct was percutaneously embolized required reoperation.
Median chest drainage for the 3 days before first attempted lymphangiogram (n = 37) was 530 ml day À1 (range 0-2700 ml day
À1
, 25% <310 ml day À1 and 25% >800 ml day
). Median chest drainage for the 10 days after first lymphangiogram without percutaneous treatment (n = 15) was 35 ml day À1 (range 0-920 ml day À1 , 25% = 0 ml day À1 and 25% >260 ml day À1 ), after first thoracic duct disruption (n = 9) was 175 ml day À1 (range 0-3200 ml day
, 25% <26 ml day
and 25% >530 ml day
) and after thoracic duct embolization (n = 12) was 100 ml day À1 (range 0 to 1120 ml day
, 25% = 0 ml day À1 and 25% >210 ml day
). Total parenteral nutrition (TPN) was instituted in 32 patients (86%) prior to lymphangiogram. Median duration of TPN after first lymphangiogram without percutaneous treatment (n = 15) was 2 days (range 1-19 days), after first thoracic duct disruption (n = 9) 7 days (range 4-40 days), and after thoracic duct embolization (n = 12) 5 days (range 2-26 days).
First percutaneous treatment (n = 21) occurred a median of 10 days after the index thoracic operation (range 6-33 days, 25% 8 days and 25% !22 days). Patients were discharged a median of 7 days (range 4-58 days, 25% <5 days and 25% >10 days) after first lymphangiogram without percutaneous intervention (n = 15), 10 days (range 2-48 days, 25% <8 days and 25% >19 days) after the first percutaneous treatment (n = 21), 8 days (range 2-19 days) after thoracic duct embolization (n = 12) and 19 days (range 6-48 days) after first thoracic duct disruption (n = 9).
Discussion
Presence of chyle in the pleural space defines chylothorax. Although a simple definition, diagnosis of chylothorax may be difficult: There is no constituent that is unique to chyle [5] ; diagnosis may be based on rapid accumulation of large quantities of chylous-appearing fluid [6] , and the gross description of chest drainage is a poor indicator of chylothorax [5, 6] . The problem is further heightened by (1) reliance on clinical diagnosis of chylothorax in the transitory postoperative course, (2) occurrence of chylothorax predominately in patients who have had esophagectomy and have not yet been fed, and (3) treatment (bowel rest and TPN) prior to lymphangiography, which may be therapeutic itself. Pleural fluid analysis and lymphangiogram were each able to confirm the diagnosis of chylothorax in about 60% of clinically diagnosed patients. Therefore, the diagnosis of chylothorax in this changing postoperative period requires clinical acumen supplemented by pleural fluid biochemical analysis and diagnostic lymphangiography.
The percutaneous treatment strategy has evolved, and the current technique is detailed under methods. Once the lymphangiogram has been performed, the treatment algorithm is as follows.
If extravasation is demonstrated, the thoracic duct below the leak is embolized with coils followed by glue distal to the coils. This is an attempt to ensure stability of the glue embolus, preventing its possible later dislodgement, and limiting its proximal spread. If no extravasation is demonstrated, but the clinical diagnosis of chylothorax has been confirmed by pleural fluid analysis, it is assumed that either the lymphangiogram is falsely negative or the leak has sealed but needs to be reinforced; in this situation, coils are used to embolize the thoracic duct. Glue is avoided in these patients in an effort to prevent its proximal and lateral spread in the lymphatic system, which could theoretically migrate intravascularly or damage developing lympho-lympho or lympho-venous collaterals. The slower occlusion offered by coils potentially allows more gradual shift of lymph flow from the thoracic duct to collateral circulation, protecting the delicate developing collaterals. If extravasation is demonstrated but the thoracic duct cannot be cannulated, usually because no definite cisterna chyli exists, needle laceration of large retroperitoneal ducts or junction of cisterna chyli and thoracic duct is attempted. Supposedly, creation of a controlled leak in the intact retroperitoneum distal to the thoracic duct leak will divert lymph flow from the damaged thoracic duct to collaterals. This study indicates that disruption is less likely to be successful than embolization. If no extravasation is demonstrated and the pleural fluid analysis is negative, no intervention is undertaken.
In all patients, slow return to oral intake and early avoidance of a fatty diet allowed time for collateral formation.
Percutaneous treatment may not immediately stop the flow of chyle; therefore, it rarely abruptly terminates chylous chest drainage. Time to develop collateral lymphatic circulation is variable and patient and procedure related. Management of clinically diagnosed chylothorax usually includes TPN, which confounds evaluation of efficacy of percutaneous treatment. Thoracic duct embolization reduces length of postoperative hospital stay to the range of those patients having lymphangiogram without percutaneous treatment (the majority of whom do not demonstrate thoracic duct leak). The value of thoracic duct disruption is questionable because of the subsequent need for reoperation in nearly half these patients.
A major limitation of this report is the evolutionary nature of this percutaneous diagnostic and treatment strategy. This report reflects our entire experience, including our earliest percutaneous attempts, lessons learned, and techniques refined.
Chylothorax continues to be a clinical challenge to diagnose and treat. Lymphangiography has a diagnostic role in chylothorax and is the platform for percutaneous intervention. Thoracic duct embolization is feasible, safe, and minimizes need for reoperation.
